Monosodium glutamate in a type 2 diabetes context: A large scoping review.

This scoping review aimed to map and elaborate the heterogenous and inconclusive body of evidence relating monosodium glutamate (MSG) and type 2 diabetes (T2DM). For this reason, multiple health outcomes related to T2DM were included and a systematic search was conducted. Experimental and observational trials between 1995 and January 2021 were collected. The tests were highly heterogenous in their samples, doses, route of exposures, durations, diets and conclusions. There was a pattern of negative effects of MSG at oral doses ≥2,000 mg/kg of body weight, and by gavage or injection at any given dose. Evidence was lacking in many areas and most of the evidence relied on short term tests. Further research should focus on standardizing and justifying methodologies, conducting long term studies and toxicokinetic tests, and avoiding bias. Focusing on the gaps highlighted and investigating mechanisms of action of MSG is crucial. Evidence-based toxicology is encouraged.

Copyright © 2022 Elsevier Inc. All rights reserved.